68
Participants
Start Date
April 30, 2006
Primary Completion Date
July 31, 2010
Study Completion Date
July 31, 2010
SB-743921
Phase 1: I.V. dose on Days 1 and 15 of a 28 day cycle starting at 2mg/m2 and increasing by 1 mg/m2 with possible prophylactic granulopoietic support until unacceptable toxicity develops.
SB-743921
Phase 2: I.V. dose and regimen will be determined based on Phase 1 findings.
Cornell University Medical Center, New York
Memorial Sloan-Kettering Caner Center, New York
Herbert Irving Comprehensive Cancer Center, New York
University of North Carolina, Chapel Hill
Sarah Cannon Cancer Research Institute, Nashville
Russian Medical Academy of Postgraduate Education, Moscow
St. Petersburg State PAVLOV Medical University, Saint Petersburg
Hackensack University Medical Center, Hackensack
Lead Sponsor
Cytokinetics
INDUSTRY